Reply

Creator(s)

Valentina Shakhnovich, Children's Mercy HospitalFollow
P. Brian Smith, Duke Clinical Research Institute
Huali Wu, Duke Clinical Research Institute
Michael Cohen-Wolkowiez, Duke Clinical Research Institute
Gregory L. Kearns, University of Arkansas for Medical Sciences

Document Type

Letter to the Editor

Publication Date

7-2018

Identifier

10.1016/j.jpeds.2018.03.001

Abstract

Comment on

• Obese Children Require Lower Doses of Pantoprazole Than Nonobese Peers to Achieve Equal Systemic Drug Exposures. Shakhnovich V, Smith PB, Guptill JT, James LP, Collier DN, Wu H, Livingston CE, Zhao J, Kearns GL; Best Pharmaceuticals for Children Act – Pediatric Trials Network.J Pediatr. 2018 Feb;193:102-108.e1. doi: 10.1016/j.jpeds.2017.10.011.PMID: 29389444 Free PMC article. Clinical Trial.
• Pantoprazole pharmacokinetics in obese children: normalized to lean or ideal weight? Friesen JHP.J Pediatr. 2018 Jul;198:327. doi: 10.1016/j.jpeds.2018.02.066. Epub 2018 Apr 19.PMID: 29681449 No abstract available.

Journal Title

Journal of Pediatrics

Volume

198

First Page

327

Last Page

328

Recommended Citation

Shakhnovich V, Smith PB, Wu H, Cohen-Wolkowiez M, Kearns GL. Reply. J Pediatr. 2018;198:327-328. doi:10.1016/j.jpeds.2018.03.001